Development of a novel molecular therapy for rheumatoid arthritis by regulation of Th1/Th2 differentiation
通过调节 Th1/Th2 分化开发治疗类风湿性关节炎的新型分子疗法
基本信息
- 批准号:14370167
- 负责人:
- 金额:$ 8.58万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2003
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Because Th1 cells are implicated in the immunopathology of rheumatoid arthritis, an understanding of molecular mechanisms of Th1fTh2 differentiation is required for development of a new therapy for rheumatoid arthritis, Th1 and Th2 cells are derived from CD4 positive naive T cells. Because CD4 positive naive T cells require intercellular binding with antigen presenting cells for differentiation of helper T cells, we investigated whether intercellular adhesion molecules on CD4 positive naive T cells may play an important role for initial triggering of differentiation of helper T cellsHere, we report that cross-linking of LFA-1 and CD3 drives Th1 differentiation from CD4 positive naive T cells from peripheral blood or cord blood cells. Addition of anti-IL-12 neutrarizing antibody did not inhibit the Th1 differentiation induced by stimulation of LFA-1. These results indicate that Th1 differentiation mediated by LFA-1 is independent on IL-12. Furthermore, we, show that lentiviral vector-mediated mutant (Y-F^<322>) CD226 transfer into naive CD4^+ helper T cells inhibited IL-12-independent Th1 differentiation initiated by CD3 and LFA-1 ligations. These results suggest that CD226 is involved in LFA-1-mediated costimulatory signals for triggering nave T helper cell differentiationIn future, we will investigate the relationship between LFA-1/CD226-mediated Th1 differentiation and the immunopathology of rheumatoid arthritis using mice with the collaoen-induced arthritis, a model for rheumatoid arthritis
由于Th 1细胞与类风湿关节炎的免疫病理学有关,因此需要了解Th 1/Th 2分化的分子机制以开发治疗类风湿关节炎的新疗法,Th 1和Th 2细胞来源于CD 4阳性幼稚T细胞。由于CD 4阳性初始T细胞需要与抗原呈递细胞细胞细胞间结合以分化辅助T细胞,我们研究了CD 4阳性初始T细胞上的细胞间粘附分子是否可能在初始触发辅助T细胞分化中起重要作用。我们报道了LFA-1和CD 3的交联驱动来自外周血或脐带血细胞的CD 4阳性初始T细胞的Th 1分化。添加抗IL-12中和抗体不抑制由LFA-1刺激诱导的Th 1分化。这些结果表明,由LFA-1介导的Th 1分化不依赖于IL-12。此外,我们发现慢病毒载体介导的突变型(Y-F^<322>)CD 226转移到初始CD 4 ^+辅助性T细胞中抑制了由CD 3和LFA-1连接启动的IL-12非依赖性Th 1分化。这些结果表明,CD 226参与了LFA-1介导的共刺激信号,触发了原始T辅助细胞分化。未来,我们将利用胶原诱导的关节炎小鼠模型,研究LFA-1/CD 226介导的Th 1分化与类风湿关节炎免疫病理学的关系
项目成果
期刊论文数量(27)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Yoh K.: "Transgenic Overexpression of GATA-3 in T Lymphocytes Improves Autoimmune Glomerulonephritis in BXSB/MpJ-Yaa Genetic Background Mice."J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
Yoh K.:“T 淋巴细胞中 GATA-3 的转基因过度表达可改善 BXSB/MpJ-Yaa 遗传背景小鼠的自身免疫性肾小球肾炎。”J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kojima H.: "CD226 mediated platelet and megakaryocytic cell adhesion to vascular endothelial cells."J.Biol.Chem.. 278. 36748-36753 (2003)
Kojima H.:“CD226 介导血小板和巨核细胞与血管内皮细胞的粘附。”J.Biol.Chem.. 278. 36748-36753 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Shibuya K.: "CD226 (DNAM-1) is involved in LEA-1 costimulatory signal for naive T cell differentiation and proliferation."J.Exp.Med.. 198. 1829-1839 (2003)
Shibuya K.:“CD226 (DNAM-1) 参与幼稚 T 细胞分化和增殖的 LEA-1 共刺激信号。”J.Exp.Med.. 198. 1829-1839 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Iwama A.: "Reciprocal roles for C/EBP and PU.I transcription factors in Langerhans cell commitment"J.Exp.Med.. 195. 547-558 (2002)
Iwama A.:“C/EBP 和 PU.I 转录因子在朗格汉斯细胞定型中的相互作用”J.Exp.Med.. 195. 547-558 (2002)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Yoh K.: "Transgenic Overexpression of DATA-3 in T Lymphocytes Improves Autoimmune Glomerulonephritis in BXSB/MpJ-Yaa Genetic Background Mice"J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
Yoh K.:“T 淋巴细胞中 DATA-3 的转基因过度表达可改善 BXSB/MpJ-Yaa 遗传背景小鼠的自身免疫性肾小球肾炎”J.Am.Soc.Nephrol.. 14. 2494-2502 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SHIBUYA Kazuko其他文献
Analysis for the variants of Fcα/μR, a novel Fc receptor for IgA and IgM, expressed in the kidney and testis.
Fcα/μR 变异体的分析,Fcα/μR 是一种新型 IgA 和 IgM Fc 受体,在肾脏和睾丸中表达。
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
USUI Kenta;HONDA Shin-ichiro;KURITA Naoki;MIYAMOTO Akitomo;CHO Yukiko;TAHARA-HANAOKA Satoko;SHIBUYA Kazuko;SHIBUYA Akira - 通讯作者:
SHIBUYA Akira
Negative regulation of IgA production by the Fca/mR, an Fc receptor for IgA and IgM.
Fca/mR(IgA 和 IgM 的 Fc 受体)对 IgA 产生的负调节。
- DOI:
- 发表时间:
2007 - 期刊:
- 影响因子:0
- 作者:
KURITA Naoki;HONDA Shin-ichiro;CHO Yukiko;USUI Kenta;TAKESHITA Kie;TAHARA Satoko;SHIBUYA Kazuko;SHIBUYA Akira. - 通讯作者:
SHIBUYA Akira.
SHIBUYA Kazuko的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SHIBUYA Kazuko', 18)}}的其他基金
Development of the molecular targeted therapy for the chronic rejection after renal transplantation that control immunological memory
控制免疫记忆的肾移植后慢性排斥反应分子靶向治疗的开发
- 批准号:
26670575 - 财政年份:2014
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of the molecular targeted therapy for allergic dermatitis
过敏性皮炎分子靶向治疗的进展
- 批准号:
25293091 - 财政年份:2013
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of the novel molecular target therapy for the graft versus host disease (GVHD) using the humanized mice
使用人源化小鼠开发针对移植物抗宿主病(GVHD)的新型分子靶向疗法
- 批准号:
24659176 - 财政年份:2012
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of a novel tumor immunotherapy that targets the soluble poliovirus receptor
开发针对可溶性脊髓灰质炎病毒受体的新型肿瘤免疫疗法
- 批准号:
22390073 - 财政年份:2010
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
A role of LFA-1 in the development of autoreactive Th17 cells
LFA-1 在自身反应性 Th17 细胞发育中的作用
- 批准号:
19390270 - 财政年份:2007
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
相似国自然基金
Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis
- 批准号:31171277
- 批准年份:2011
- 资助金额:60.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Tissue tropism of PD-1 therapy in ulcerative colitis and rheumatoid arthritis
PD-1治疗溃疡性结肠炎和类风湿性关节炎的组织向性
- 批准号:
MR/Y009681/1 - 财政年份:2024
- 资助金额:
$ 8.58万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 8.58万 - 项目类别:
Research Grant
The delivery of miR-9 and RasGRP4 siRNA via high selectivity bispecific antibody conjugated lactosome: Targeting therapy for rheumatoid arthritis (RA) active synovial macrophage and osteoclast
通过高选择性双特异性抗体缀合乳糖体递送 miR-9 和 RasGRP4 siRNA:类风湿性关节炎 (RA) 活性滑膜巨噬细胞和破骨细胞的靶向治疗
- 批准号:
24K19237 - 财政年份:2024
- 资助金额:
$ 8.58万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Development of an adaptive platform trial to prevent Rheumatoid Arthritis in partnership with First Nations People.
与原住民合作开发预防类风湿关节炎的适应性平台试验。
- 批准号:
491810 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
Operating Grants
DEMORA: DEep spatial characterization of synovial MacrOphages in Rheumatoid Arthritis
DEMORA:类风湿性关节炎滑膜巨噬细胞的深度空间特征
- 批准号:
EP/Y027760/1 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
Fellowship
The roles and mechanisms of inflammation resolution in the development of Rheumatoid Arthritis
炎症消退在类风湿关节炎发展中的作用和机制
- 批准号:
10733789 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
Microbial metabolites impacting the response to methotrexate in rheumatoid arthritis
微生物代谢物影响类风湿性关节炎对甲氨蝶呤的反应
- 批准号:
10578433 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
Novel first-in-class Therapeutics for Rheumatoid Arthritis
类风湿关节炎的一流新疗法
- 批准号:
10696749 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
A Potent D-peptide Inhibitor of TNFα for Treatment of Rheumatoid Arthritis
一种有效的 TNFα D 肽抑制剂,用于治疗类风湿性关节炎
- 批准号:
10822182 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别:
Fibroblast-mediated inflammatory resolution of rheumatoid arthritis
成纤维细胞介导的类风湿性关节炎炎症消退
- 批准号:
10604629 - 财政年份:2023
- 资助金额:
$ 8.58万 - 项目类别: